Buyout talk played a big role in several stocks' moves.
News & Analysis: Achillion Pharmaceuticals
Alexion Pharmaceuticals will reportedly buy clinical-stage rival Achillion Pharmaceuticals in an all-cash deal.
Investors are responding enthusiastically to a key FDA designation for the biotech's leading pipeline candidate.
Positive results announced earlier this week from an early-stage study led to another day of big gains for this clinical-stage biotech.
The biotech stock is enjoying a second day of big gains after the company reported promising results for experimental drug ACH-5228.
Find out how these stocks helped lead the overall market higher.
Great results from an early-stage clinical study provided a big boost to this small biotech.
The clinical-stage biotech didn't have any revenue in the first quarter. But it made progress in several key areas.
Reaching a key clinical study milestone provided a nice boost to the biotech stock.
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.